AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+14.73%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$676M
AUM Growth
+$37.5M
(+5.9%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-4.32%
Top 10 Holdings %
Top 10 Hldgs %
50.78%
Holding
109
New
10
Increased
20
Reduced
23
Closed
14
Top Buys
| 1 |
Insmed
INSM
|
$33.7M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$32M |
| 3 |
Ventyx Biosciences
VTYX
|
$9.71M |
| 4 |
Lexeo Therapeutics
LXEO
|
$8.48M |
| 5 |
Enliven Therapeutics
ELVN
|
$8.02M |
Top Sells
| 1 |
Apogee Therapeutics
APGE
|
$19.9M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 3 |
Merus
MRUS
|
$13.3M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$8.5M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$8.47M |
Sector Composition
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Tourmaline Bio
TRML
$645M
| – | – |
0
| – | – |
|
102
Viking Therapeutics
VKTX
$3.02B
| – | – |
-25,000
| Closed | -$604K |
|
103
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
|
MBX
104
MBX Biosciences, Inc. Common Stock
MBX
$484M
| – | – |
-175,000
| Closed | -$1.29M |
|
|
MAZE
105
Maze Therapeutics, Inc. Common Stock
MAZE
$666M
| – | – |
-250,000
| Closed | -$2.75M |
|